Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Deferred Royalty Obligation [Line Items]
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net	$ 149,114
Vaxcyte, Inc. ('Vaxcyte")
Deferred Royalty Obligation [Line Items]
Proceeds from the sale of future Vaxcyte royalties	140,000
Issuance costs	(3,792)
Non-cash interest expense associated with the sale of future Vaxcyte royalties	12,570
Amortization of issuance costs	336
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net	$ 149,114